Why the study?
Does measurement of cord serum prebeta-beta-lipoprotein identify infants with familial type II hyperlipoproteinemia?
Does measurement of cord serum prebeta-beta-lipoprotein identify infants with familial type II hyperlipoproteinemia?
Cord serum prebeta-beta-lipoprotein measurement can identify familial type II hyperlipoproteinemia in neonates, provided transient hyperlipidemias are excluded.
Answers are grounded in this paper and cite their sources.
May support cord blood screening to identify neonatal familial type II hyperlipoproteinemia; leaves open routine adoption pending validation in larger cohorts.
Cord serum prebeta-beta-lipoprotein concentration was measured in a radial immunodiffusion assay in 303 randomly selected, full-term infants whose parental phenotypes were unknown. Six infants had elevated concentrations, that is above a cut-off limit of 197 mg/100 ml (97.5th percentile). Three of these infants suffered from classic type II hyperlipoproteinemia, and this diagnosis was confirmed by family studies at follow-up. The three other infants and their parents were shown to be normolipemic at follow-up. The elevated cord serum prebeta-beta-lipoprotein in these three infants could be explained by highly elevated cord serum triglyceride and/or cholesterol. The 297 infants with normal cord serum prebeta-beta-lipoprotein and their parents were all shown to be normalipemic at follow-up. It is concluded that the measurement of prebeta-beta-lipoportein in cord serum allows the identification of children with familial type II hyperlipoproteinemia, if infants with transient neonatal hypertriglyceridemia and hypercholesterolemia are excluded.
No takes yet. Share an insight, caveat, or question.
ANDERSEN et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: